Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transdermal Nicotine for Aggression in Autism
NCT02552147Phase 1Completed
- Sponsor
- Yale University
- Start
- Sep 2015
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Nicotine First with Placebo First (2 arms). Primary endpoint: Aberrant Behavior Checklist Irritability Subscale at 7 days. Started Sep 2015; status: completed.
02
Drugs
nicotine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02552147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02552147.